Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Takeda
Thomas Jefferson University
Novartis
University of Pittsburgh
Dartmouth-Hitchcock Medical Center
Takeda
Pfizer
Novartis
National Institutes of Health Clinical Center (CC)
University of Wisconsin, Madison
University of Wisconsin, Madison
Stanford University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Il-Yang Pharm. Co., Ltd.
University of Kansas Medical Center
National Institutes of Health Clinical Center (CC)
Il-Yang Pharm. Co., Ltd.
Merck Sharp & Dohme LLC
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Technische Universität Dresden
National Institutes of Health Clinical Center (CC)